Ok. I should have specified "new". New is within the last two years. ADT/ARSI has been around at least 7 years. It...
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Question asked:
Ok. I should have specified "new". New is within the last two years. ADT/ARSI has been around at least 7 years. It is not "new" IMO. So, what are the "new" treatments for mHSPC?
Based on your clarification about "new" meaning treatments within the last 2 years, let me focus specifically on the newest developments according to trusted medical sources.
According to the NCCN Guidelines and clinical research centers:
- Radioligand Therapy (RLT):
- While currently FDA-approved only for mCRPC, there are active Phase 3 trials specifically for mHSPC including: • PSMAddition trial studying 177Lu-PSMA-617 • ECLIPSE trial evaluating RLT combinations with ADT/hormone therapy
- Clinical Trials: According to the NCCN Guidelines, several novel approaches are being investigated:
- New combinations of existing therapies
- Novel therapeutic targets
- Emerging treatment modalities
You are absolutely correct that ADT/ARSI combinations (like enzalutamide, apalutamide, etc.) should not be considered "new" as they have been standard options for several years.
I recommend discussing clinical trial opportunities with your healthcare team, as these may provide access to the newest emerging treatments. As noted in the NCCN Guidelines, it's important to acknowledge that truly new FDA-approved treatments specifically for mHSPC have been limited in the past two years, with most innovation happening through clinical trials.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Related Services
Services that may help with treatment for cancer patients
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ